% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Koskinen:180113,
      author       = {A. Koskinen and O. Hemminki and A. Försti$^*$ and K.
                      Hemminki$^*$},
      title        = {{I}ncidence and survival in laryngeal and lung cancers in
                      {F}inland and {S}weden through a half century.},
      journal      = {PLOS ONE},
      volume       = {17},
      number       = {5},
      issn         = {1932-6203},
      address      = {San Francisco, California, US},
      publisher    = {PLOS},
      reportid     = {DKFZ-2022-01106},
      pages        = {e0268922 -},
      year         = {2022},
      abstract     = {Global survival studies have shown favorable development in
                      most cancers but few studies have considered laryngeal
                      cancer, particularly over extended periods or in populations
                      for which medical care is essentially free of charge. We
                      analyzed laryngeal and lung cancer incidence and survival in
                      Finland (FI) and Sweden (SE) over a 50-year period
                      (1970-2019) using data and statistical tools from the
                      Nordcan database. Laryngeal cancer reached an incidence
                      maximum in FI men in 1965, which in SE men occurred over 10
                      years later and peaking at $42\%$ of the FI maximum. The FI
                      incidence halved in 20 years while halving of the SE rate
                      took almost twice as long. At maximum the male rate exceeded
                      the female rate 20 times in FI and 10 times in SE. Incidence
                      rates for lung cancer were approximately 10 times higher
                      than those for laryngeal cancer, and they peaked 5 to 10
                      years after laryngeal cancer in both countries. The female
                      lung cancer rates increased through the follow-up time but
                      laryngeal cancer rates were relatively stable. Relative
                      1-year survival data for laryngeal cancer remained at around
                      $85\%$ through 50 years, and 5-year survival lagged
                      constantly around $65\%.$ For lung cancer 1-year survival
                      improved and reached about $50\%$ by 2019. Even 5-year
                      survival improved reaching 20 to $30\%,$ except for FI men.
                      Incidence rates for laryngeal and lung cancers have
                      drastically decreased in FI and SE men parallel to reduced
                      smoking prevalence. In females, rates have clearly increased
                      in lung but not in FI laryngeal cancer. This finding
                      warrants further investigations into possible contributing
                      factors, other than smoking. Survival in laryngeal cancer
                      has not improved compared to the positive development in
                      lung cancer. Historical smoking prevalence was unrelated of
                      survival trends. As long-term survival in these cancers
                      remains discouraging, the most efficient way to fight them
                      is to target the main cause and promote non-smoking.},
      cin          = {B062 / HD01},
      ddc          = {610},
      cid          = {I:(DE-He78)B062-20160331 / I:(DE-He78)HD01-20160331},
      pnm          = {312 - Funktionelle und strukturelle Genomforschung
                      (POF4-312)},
      pid          = {G:(DE-HGF)POF4-312},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:35622857},
      doi          = {10.1371/journal.pone.0268922},
      url          = {https://inrepo02.dkfz.de/record/180113},
}